Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study

Abstract Ravulizumab is a second-generation C5i engineered from eculizumab to achieve immediate, complete, and sustained inhibition of terminal complement activity in PNH. The REACTION observational cohort study describes the effectiveness and tolerability of ravulizumab in Italian patients who were...

全面介紹

書目詳細資料

Principais autores:	Anna Paola Iori, Antonio De Vivo, Eros Di Bona, Giovanni Caocci, Francesca Fioritoni, Fabio Ciceri, Eloise Beggiato, Davide Rapezzi, Angela Amendola, Amalia Figuera, Carmine Selleri, Francesco Longu, Bruno Fattizzo, Alessandra Tucci, Alessandro Cignetti, Valeria Amico, Simona Sica, Elisabetta Metafuni, Simona Raso, Tiziana Anna Urbano, Luana Marano, Nicola Di Renzo, Pierangelo Spedini, Alessandro Rambaldi, Francesco Lanza, Cristina Clissa, Cristina Danesin, Maria Bruna Greve, Sergio Cabibbo, Alessandra Ori, Francesca Cassanelli, Federica Sottana, Benedetta Campolo, Giulia Gasparri, Fabio Carini, Wilma Barcellini
格式:	Artigo
語言:	Inglês
出版:	Springer 2026-01-01
叢編:	Annals of Hematology
主題:	Paroxysmal nocturnal hemoglobinuria Ravulizumab Lactate dehydrogenase Breakthrough hemolysis Health-related quality of life
在線閱讀:	https://doi.org/10.1007/s00277-026-06792-w
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!